Keynote Address at 8th Annual Photodynamic Day

Ondine Biomedical Inc.

01 July 2026

 

1 July 2026

ONDINE BIOMEDICAL INC.

("Ondine Biomedical", "Ondine", or "the Company")

Ondine Biomedical Keynote Address at 8th Annual Photodynamic Day in Türkiye

Ondine Biomedical Inc. (AIM: OBI), a leader in light-activated antimicrobial therapies to prevent and treat hospital infections, announces that Dr. Nicolas Loebel, President and Chief Technology Officer, delivered the keynote address at the 8th Annual Photodynamic Day in Istanbul, Türkiye, on 25 June 2026. This prestigious invitation reflects Ondine's growing global recognition within the photodynamic therapy (PDT) community for its pioneering work in advancing antimicrobial photodynamic therapy (aPDT), also known as photodisinfection.

Hosted by Acıbadem University under the stewardship of Professor Fabienne Dumoulin, a leading authority on photodynamic photosensitisers, and held in conjunction with the International Photodynamic Association (IPA), the event brought together leading researchers, clinicians and industry experts working to advance photodynamic therapy ahead of the 20th IPA World Congress, which will take place in Türkiye from 12-16 July 2027. The event also provided an opportunity to engage with international clinical and scientific leaders as photodisinfection continues to gain momentum as a non-antibiotic approach to infection prevention.

During his keynote, Dr. Loebel presented clinical and real-world evidence from leading healthcare institutions in the United Kingdom and Canada, demonstrating the potential of Ondine's non-antibiotic nasal photodisinfection technology, Steriwave^® to reduce surgical site infections ("SSIs") across multiple surgical specialties, while supporting improved patient outcomes and cost savings to healthcare systems.

The presentation also highlighted the growing body of evidence supporting antimicrobial photodisinfection as a clinician-led, non-antibiotic approach to infection prevention. As healthcare systems seek effective strategies to address healthcare-associated infections and antimicrobial resistance ("AMR"), photodisinfection has the potential to support antimicrobial stewardship while helping reduce the clinical and economic burden of healthcare-associated infections. Dr Loebel also provided an update on the Company's recently completed LANTERN Phase 3 clinical trial, which enrolled 5,188 patients across 18 hospitals in the United States and Canada. Ondine's light-activated antimicrobial technology, commercially available as Steriwave® in certain international jurisdictions, is not approved, cleared, or commercially available for sale or clinical use in the United States. In the United States, this technology is strictly limited by U.S. law to investigational use only under the LANTERN clinical trial.

Dr. Nicolas Loebel, President and Chief Technology Officer at Ondine Biomedical, said:

"Photodisinfection represents a new approach in infection prevention prior to surgery and in intensive care. Rather than targeting a narrow, mutable microbial pathway, our light-activated technology provides broad-spectrum antimicrobial activity against a wide range of pathogens, including bacteria, viruses and fungi, through a clinician-led treatment delivered immediately before surgery or upon ICU admission. It was a privilege to share Ondine's experience with leading international experts working in photodynamic therapy. We believe the growing body of real-world evidence is supporting the broader adoption of photodisinfection as a non-antibiotic approach to infection prevention."

Steriwave is a clinician-administered nasal photodisinfection treatment that is completed in approximately five minutes immediately before surgery or on admission to intensive care. Unlike traditional pre-surgical nasal decolonisation, which often relies on several days of patient-administered antibiotics or antiseptics, Steriwave is delivered entirely within the clinical setting, supporting consistent treatment delivery and patient compliance.

Clinical and real-world studies have demonstrated the potential of Steriwave to reduce surgical site infections across a range of surgical specialties while supporting antimicrobial stewardship through its non-antibiotic approach. Recent studies from the UK presented by Ondine and its clinical collaborators include a 78%¹ reduction in surgical site infections in complex brain surgery at Leeds Teaching Hospitals and a 71%² reduction in hip and knee arthroplasty infections at Mid Yorkshire Teaching NHS Trust, together with encouraging health economic outcomes.

References:

^1. Nix, P., Tyagi, A., Phillips, N. and Sheikh, A. (2026). Steriwave® a Non-Antibiotic Nasal Photodisinfection Strategy Reduces Infection Burden in Endoscopic Skull Base Surgery. The Journal of Laryngology & Otology. Published online 23 June 2026. https://doi.org/10.1017/S0022215126105179

² Sinclair, S., Hickok, J., Loebel, N., et al. (2025). Early Economic Evaluation of Nasal Photodisinfection Therapy for the Prevention of Surgical Site Infections. Conference poster presented at ICPIC 2025 - International Conference on Prevention & Infection Control, Geneva, Switzerland.

Enquiries:

Ondine Biomedical Inc.	www.ondinebio.com
Carolyn Cross, CEO	[phone] or via 5654 & Company
Strand Hanson Limited (Nominated & Financial Adviser)
James Harris, Richard Johnson, Imogen Ellis	[phone]
Peel Hunt LLP (Broker & Joint Financial Adviser)
James Steel, Dr. Chris Golden	[phone]
5654 & Company (Financial PR and IR Adviser)	[e-mail]
Matthew Neal, Chris Gardner, Melissa Gardiner	[phone] [phone]

About Acıbadem Mehmet Ali Aydınlar University (ACU)

Founded in 2007, Acıbadem University is a premier, research-driven institution in Istanbul, Türkiye, dedicated exclusively to health sciences, life sciences, and biomedical engineering. Backed by the extensive network of the Acıbadem Healthcare Group, the university features the Center of Advanced Simulation and Education (CASE), one of the world's most advanced medical training facilities. Spanning a modern, LEED Gold-certified campus, ACU acts as a vital global bridge for clinical innovation, matching pioneering academic research with real-world health technology deployment and advanced photomedicine.

About Ondine Biomedical Inc.

Ondine Biomedical Inc. is a Canadian life sciences company focused on the development of light-activated antimicrobial therapies ("photodisinfection") for the prevention and treatment of infections, including those associated with multidrug-resistant organisms.

Ondine's lead product, Steriwave^®, is authorized for nasal decolonisation in Canada and certain international markets. In the United States, the technology has been granted Qualified Infectious Disease Product designation and Fast Track status by the U.S. Food and Drug Administration and recently completed enrolment in its Phase 3 clinical trial.

The Company has a pipeline of additional photodisinfection products in various stages of development for application in areas including chronic sinusitis, ventilator-associated pneumonia, burns and other indications.

U.S. Regulatory Status and Clinical Data Disclaimer

Ondine's light-activated antimicrobial technology, commercially available as Steriwave® in certain jurisdictions, is not approved, cleared, or commercially available for sale or clinical use in the United States and is limited by U.S. law to investigational use only. References to clinical outcomes in this release should be interpreted in the context of the specific studies or real-world evaluations described and do not imply regulatory approval for any particular indication.

 

END